Thursday, 15 October 2026European Markets

CRCAM LANGUED CCI And SPAREBANKEN VEST Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - crcam langued cci (crla.pa) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
crcam langued cci (crla.pa) €50.50 5.45% 4.61%
sparebanken vest (sveg.ol) kr109.00 5.25% 14.56%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. crcam langued cci (crla.pa)

5.45% forward dividend yield and 4.61% return on equity

caisse régionale de crédit agricole mutuel du languedoc société coopérative provides various banking products and services to individuals, professionals and associations, farmers, businesses, private banking customers, and public and social housing community clients in france. the company offers accounts and cards; savings products; loans; real estate and consumer loans; business creation, medium and long term, and other financing services; leasing, cash management, treasury, and advisory services. it also provides car and two wheeler, home, health and death, leisure and daily life, professional premises and vehicle, activity, employee, agricultural building and equipment, borrower, and other insurance products; and pension solutions. the company was incorporated in 2006 and is headquartered in lattes, france. caisse régionale de crédit agricole mutuel du languedoc société coopérative is a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam langued cci has a trailing twelve months eps of €10.91.

pe ratio

crcam langued cci has a trailing twelve months price to earnings ratio of 4.63. meaning, the purchaser of the share is investing €4.63 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.61%.

volume

today's last reported volume for crcam langued cci is 201 which is 54.72% below its average volume of 444.

more news about crcam langued cci.

2. sparebanken vest (sveg.ol)

5.25% forward dividend yield and 14.56% return on equity

sparebanken vest, a financial services company, provides banking and financing services in the counties of vestland and rogaland, norway. the company operates through corporate market, retail market, bulder bank, treasury, and estate agency activities segments. it is also involved in home mortgage activities. the company was founded in 1823 and is headquartered in bergen, norway.

earnings per share

as for profitability, sparebanken vest has a trailing twelve months eps of kr10.66.

pe ratio

sparebanken vest has a trailing twelve months price to earnings ratio of 10.23. meaning, the purchaser of the share is investing kr10.23 for every norwegian krone of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.56%.

growth estimates quarters

the company's growth estimates for the present quarter is 35.7% and a drop 8% for the next.

revenue growth

year-on-year quarterly revenue growth grew by 11.2%, now sitting on 5.33b for the twelve trailing months.

sales growth

sparebanken vest's sales growth is 29.6% for the present quarter and 2.7% for the next.

dividend yield

as stated by morningstar, inc., the next dividend payment is on mar 23, 2023, the estimated forward annual dividend rate is 5.5 and the estimated forward annual dividend yield is 5.25%.

more news about sparebanken vest.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com